Hydroxycarbamid Devatis

Hydroxycarbamide, the active ingredient in Hydroxycarbamid Devatis, is an antimetabolite (ribonucleotide reductase inhibitor) presented as an oral formulation for systemic use. It is employed in the management of certain hematologic malignancies and blood disorders, including chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, sickle cell disease, and melanoma.

GNH USA supplies Hydroxycarbamid Devatis as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Hydroxycarbamide is used to treat several hematologic and oncologic conditions by targeting abnormal cell proliferation. - Chronic myelogenous leukemia: reduces leukemic cell burden and improves hematologic control. - Polycythemia vera: lowers elevated red blood cell mass and decreases risk of thrombosis. - Essential thrombocythemia: controls platelet overproduction and reduces thrombotic complications. - Sickle cell disease: decreases frequency of vaso‑occlusive crises by raising fetal hemoglobin levels. - Melanoma: used as part of combination therapy to inhibit tumor growth in advanced disease.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue or weakness - Mild skin discoloration (hyperpigmentation) - Transient elevation of liver enzymes - Low white blood cell count (leukopenia)

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia - Acute pulmonary toxicity (interstitial pneumonitis) - Renal impairment or failure - Severe cutaneous reactions such as Stevens‑Johnson syndrome

When prescribing hydroxycarbamide, clinicians should consider several safety measures to minimize risks. - Baseline blood counts: obtain complete blood count before initiation and monitor regularly. - Liver function: assess hepatic enzymes prior to therapy and during treatment. - Renal function: evaluate kidney function and adjust use in impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with patient. - Drug interactions: review concomitant medications for potential additive myelosuppression. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Hydroxycarbamide can interact with other agents, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive drugs (e.g., azathioprine, cyclophosphamide): may cause profound bone marrow depression. - Strong CYP2C9 inhibitors (e.g., fluconazole): can increase hydroxycarbamide plasma levels and toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): hydroxycarbamide may enhance anticoagulant effect, requiring INR monitoring. - Allopurinol: may increase risk of hematologic toxicity; monitor blood counts. - Live vaccines: immunosuppression may reduce vaccine efficacy; assess timing.